Blood component use in critical care in patients with COVID-19 infection: a single-centre experience.
Andrew J DoyleAnicee DanaeeCharlene I FurtadoScott MillerTim MaggsSusan E RobinsonAndrew RetterPublished in: British journal of haematology (2020)
There has been a significant surge in admissions to critical care during the coronavirus disease 2019 (COVID-19) pandemic. At present, the demands on blood components have not been described. We reviewed their use during the first 6 weeks of the outbreak from 3 March 2020 in a tertiary-level critical care department providing venovenous extracorporeal membrane oxygenation (vv-ECMO). A total of 265 patients were reviewed, with 235 not requiring ECMO and 30 requiring vv-ECMO. In total, 50 patients required blood components during their critical care admission. Red cell concentrates were the most frequently transfused component in COVID-19-infected patients with higher rates of use during vv-ECMO. The use of fresh frozen plasma, cryoprecipitate and platelet transfusions was low in a period prior to the use of convalescent plasma.
Keyphrases
- extracorporeal membrane oxygenation
- acute respiratory distress syndrome
- coronavirus disease
- end stage renal disease
- respiratory failure
- newly diagnosed
- ejection fraction
- chronic kidney disease
- emergency department
- sars cov
- peritoneal dialysis
- stem cells
- mechanical ventilation
- single cell
- intensive care unit
- cell therapy
- patient reported
- preterm birth